1. Introduction {#sec1}
===============

Patients presenting with Pulmonary Nodular and cystic lesion can represent wide differential diagnosis. Similarly, variety of pulmonary manifestations have been described in literature in association with Sjogren\'s syndrome, the most common of which are interstitial lung disease (ILD) and tracheobronchial disease \[[@bib1]\]. Amyloidosis secondary to Sjogren\'s syndrome manifesting as nodule-cystic lung disease is infrequently reported, more so in Australian indigenous population \[[@bib2], [@bib3], [@bib4], [@bib5]\]. We describe herewith a case of 52-year-old Australian Indigenous woman with a known history of primary Sjogren\'s syndrome, who presented with chronic cough and was found to have Pulmonary AL Amyloidosis after extensive investigation of the lung lesions which were initially masquerading as lung malignancy.

1.1. Case {#sec1.1}
---------

A 52-year-old Australian Indigenous women presented with 6 months history of dry cough. There were no other respiratory symptoms. She did not have any constitutional symptoms, in particular no history of fever, anorexia or unintentional weight loss. She denied any history or known contact for tuberculosis.

Her past medical history included Sjogren\'s syndrome, initially diagnosed at the age of 42 years and had clinical manifestation of sicca syndrome, xeropthalmia and xerostomia (dry eyes and dry oral cavity). She had a family history for breast cancer, Sjogren\'s syndrome and Systemic Lupus Erythematosus. She had a very insignificant history of smoking as a teenager. She was not on any regular medications other than NSAID for nonspecific back pain.

Physical examination was un-remarkable other than for an enlarged thyroid gland. There was no palpable lymphadenopathy, clubbing or other signs of connective tissue disease. Respiratory examination was normal, in particular there were no crackles to suggest presence of interstitial lung disease.

Laboratory examination demonstrated normal white cell/differential count. Serum electrolytes and liver function testes were also normal. Her ESR was elevated at 38mm/h, anti-nuclear antibody (ANA) titre was raised with a titre of 1:1280 demonstrating a speckled and nucleolar pattern. Extractable nuclear antigen (ENA) was positive for SS-A (Ro) and SS-B (La) and other ENA such as RNP, Sm, Scl -- 70 and Jo-1 including ds-DNA antibody were negative. Thyroid function test was also normal, HIV and hepatitis serology were negative. Serum immunoglobulin showed slightly elevated IgG level at 17.7 (6.5--16.0) and IgA and IgM were normal. Pulmonary function test was normal with a Forced Vital Capacity (FVC) of 3.00L (88%), Forced Expiratory Volume in 1 second (FEV^1^) was 2.55L (94%) with FEV^1^/FVC Ratio of 0.85 (107%). The Gas transfer (DLCO) was normal at 86% and the lung volumes were preserved with Total lung Capacity (TLC) at 80% predicted respectively.

A CT of the chest performed demonstrated multiple pulmonary nodules bilaterally, including a solitary non-calcified multilobulated opacity in the right lower lobe (RLL) measuring 28 × 17 mm with slight speculation ([Fig. 1](#fig1){ref-type="fig"}). The CT scan also demonstrated multiple bilateral pulmonary cysts. ([Fig. 1](#fig1){ref-type="fig"}). There was no evidence of Interstitial Lung Disease (ILD) or hilar or mediastinal lymphadenopathy. Incidental retrosternal extension of the enlarged thyroid gland was noted. Ultra sound of the thyroid gland demonstrated benign cystic lesion. A high index for malignancy with multiple metastasis was considered in the differential diagnosis. Hence, she underwent a bronchoscopy, which did not demonstrate endobronchial abnormalities and washings were negative for malignant cells and acid-fast bacilli. Cultures were negative for Acid fast bacilli (AFB), bacterial or fungal elements. She underwent a PET scan which showed positive uptake in the right lower lobe lesion with an SUV of 4.2, suspicious for malignancy and included in the differential of possible inflammatory process ([Fig. 2](#fig2){ref-type="fig"}). A percutaneous CT guided biopsy of the right lower lobe lesion was attempted, which was unfortunately complicated by an iatrogenic pneumothorax, and the results were inconclusive. In order to make a definitive diagnosis she underwent a video assisted thoracotomy with a wedge excision of the RLL nodule. Surprisingly, the biopsy showed evidence of amorphous material and demonstrated apple-green birefringence under polarised light after staining with Congo-Red in keeping with pulmonary AL amyloidosis ([Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}). In-situ hybridisation with kappa and lambda stains showed preferential kappa staining ([Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}). Biopsy results also identified Immunoglobulin heavy chain, with rearrangement studies demonstrating polyclonal lymphocyte population in pulmonary infiltrate. Serum electrophoresis did not identify paraprotein with free light chains showing Kappa 29 mg/L (3--19), Lambda 26 mg/L (6--26) and K/L Ratio of 1.11 (0.25--1.65). In order to exclude systemic AL amyloid, patient underwent bone marrow biopsy and skeletal survey, which were normal. Her cough improved with symptomatic management. As localized AL amyloidosis has a very low likelihood of systemic dissemination she remains on surveillance and was not offered systemic treatment as she had interval symptom resolution.Fig. 1CT chest showing multiple cystic lesions and right lower lobe nodule.Fig. 1Fig. 2PET-CT scan showing positive uptake in the right lower lobe.Fig. 2Fig. 3Low power image showing normal lung vs amyloid.Fig. 3Fig. 4High power image showing lung amyloid with multinucleated giant cells.Fig. 4Fig. 5Biopsy showing evidence of birefringence under polarised light after staining with Congo-Red.Fig. 5

1.2. Discussion {#sec1.2}
---------------

Our case represents a rare presentation of nodular and cystic pulmonary lesions demonstrated on CT chest diagnosed to have pulmonary amyloidosis in an Australian Indigenous female in association with Sjogren\'s syndrome. The patient initial presentation resembled metastatic lung cancer and our case highlights the importance of keeping a broad-minded approach as amyloidosis may mimic and affect prognostication and management. It also reflects the role of surgical lung biopsy in making accurate diagnosis.

Amyloidosis is a large group of rare disorders caused by mis-folding of autologous proteins and their subsequent deposition resulting in dysfunction of organs. The two most common forms are light chain (AL) and reactive (AA) amyloidosis \[[@bib3],[@bib6]\]. Involvement of the lung in Amyloidosis is relatively common. It can occur as isolated pulmonary amyloidosis or more commonly systemic amyloidosis with another organ involvement \[[@bib5],[@bib6]\]. Lung diseases associated with chronic inflammation (such as bronchiectasis) can lead to systemic AA (apolipoprotein serum amyloid A) amyloidosis. Similarly, respiratory manifestations are common in systemic amyloidosis. Finally, amyloidosis can involve lung parenchyma or the respiratory tract. From the clinician\'s perspective, amyloidosis-related lung disease mainly manifests in three different forms: Nodular pulmonary amyloidosis, Diffuse alveolar-septal amyloidosis and tracheobronchial amyloidosis \[[@bib3]\]. These have been described in [Table 1](#tbl1){ref-type="table"}. Nodular Amyloidosis vary in distribution and can be solitary or multiple \[[@bib7],[@bib8]\]. Tracheobronchial amyloidosis present endoscopically as Amyloid deposits are confirmed with tissue biopsy and by using Congo red staining on polarized light microscopy \[[@bib1]\], further analysis to improve amyloid characterization include laser microdissection and mass spectrometry \[[@bib9]\]. Further, a link between amyloidosis and cancer has been reported frequently. There have been previous reports of localized low-grade B Non-Hodgkin lymphoma with localized amyloid deposition in tissues \[[@bib10],[@bib11],[@bib13]\]. Amyloidosis patients are also at increased risk of myeloma and squamous cell cancer \[[@bib12]\]. The mechanism is thought to be increased production of amyloid precursor proteins or peptides by tumours in AL amyloidosis with malignant transformation caused by chronic stimulation or inflammation \[[@bib13],[@bib14]\]. It is difficult to reliably differentiate nodular amyloidosis from lung cancer as they mimic in appearance. Amyloid lung nodules can have positron emission tomography (PET) uptake. This is though less common with only seven previously published cases in English literature which causes deception for lung cancer. It is difficult to reliably differentiate clinico-radiologically the two despite noted associations of amyloidosis with Sjogren syndrome, Lymphoma or Myeloma and histological examination is necessary. In most reported cases as well as ours, surgical lung biopsy is required to reach a definitive diagnosis \[[@bib4]\] and rule out lung primary or metastasis or lymphoma. This affects treatment decisions and prognostication.Table 1Pulmonary manifestations of amyloidosis.Table 1Pulmonary Involvement in AmyloidosisPulmonary Interstitial Amyloidosis or diffuse alveolo-septal amyloidosisNodular AmyloidosisTracheobronchial AmyloidosisAmyloidosis subtypeSystemic AL amyloidosis (Upto 90% cases), Sometimes, Systemic AA, ATTRwt, hereditary ATTR.\
Rarely LocalizedUsually Localized AL (Light chain) or AL/AH type (mixed light chain/heavy chain)Localized AL amyloidosis, Co-localization tracheal and laryngealAge/DemographicsMean Age 60 yearsMean age 67 years,\
Male: Female = 3: 2Mean age: 50 years\
No sex predilectionClinical PresentationUsually identified post-mortem as lung involvement rarely dominates clinical picture\
Else, Interstitial Lung disease\
Usually have pulmonary hypertension, heart failure with restrictive cardiomyopathyAsymptomatic\
Incidental DiagnosisSymptomatic Cough, haemoptysis, Stridor, Dyspnea, Wheezing, Recurrent pneumonia, atelectasis\
**BRONCHOSOPY:** Irregular whitish deposits, diffuse, fragile typically posterior trachea wall narrowing airway multifocal submucosal plaquesPathophysiology and RadiologyReticular opacities, interlobular septal thickening, micronodules, ground-glass opacification, traction bronchiectasis and honeycombing, Mediastinal Lymphadenopathy can be presentNodules peripheral subpleural distribution, can be bilateral, variable size, unusual cystic changes have been described. Slow growthTracheal and bronchial wall thickening with possible calcificationPulmonary Function TestRestrictive pattern with hypoxemia on exertionMay be normal or slight restrictive with preserved gas transfer•Fixed airflow obstruction if subglottic amyloidosis•Proximal airway: Decreased airflows and Distal airway disease: Normal airflows.Association1.Component of systemic amyloidosis2.B-Cell malignancy3.Rarely Medullary Carcinoma of Thyroid1.Mucosa-associated lymphoid tissue (MALT lymphoma)2.Sjogren Syndrome3.Multiple Myeloma, MGUS, WMRare association with multiple myelomaDifferential Diagnosis•Light Chain Deposition disease: Similar radiology but Congo-Red negative•Interstitial Lung disease- IPF, Fibrotic NSIP, HP, Sarcoidosis, CTD related•Lung Cancer, Pulmonary Metastasis•Pulmonary Hyalinizing Granuloma•Light Chain Deposition disease•Asthma•Endobronchial Tuberculosis or Cancer•PneumoniaHistopathology•Deposits vascular and the interstitial septa•Lesions typically hypocellular, Scant plasma cells•Well circumscribed•Homogenous densely eosinophilic material•Aggregates of plasma cells and lymphocytes•Kappa chain \> Lambda•Deposits localized to submucosa and blood vessels•Often with plasma cells and giant cell aggregatesTreatmentTreatment of systemic amyloidosis, ChemotherapyConservative Surgical Excision, May be left alone once diagnosis conformed, Occasional cases may need chemotherapy if progression.Laser or forceps debridement or external beam radiation. Repeated bronchoscopic intervention, stentsPrognosisPoorExcellent PrognosisDepends on the extent and distribution

Pulmonary involvement in patients with Sjogren\'s syndrome is varied and becoming more widely understood and is estimated to occur in between 9 and 20% of patients with Primary Sjogren\'s Syndrome \[[@bib1],[@bib3]\], though cough can be present in upto 60% cases. The presentations described include multiple cysts or nodules, bronchiectasis and lymphoproliferative Disease \[[@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6]\]. These are described in [Table 2](#tbl2){ref-type="table"}. Pulmonary amyloidosis secondary to Sjogren\'s syndrome has been reported infrequently in the literature \[[@bib3]\]. Our patient\'s CT chest findings demonstrated both multiple pulmonary nodules and multiple cysts. In concordance with most other reports in the literature, our case identified the AL form of amyloidosis in a woman.Table 2Respiratory involvement in Sjogren\'s syndrome.Table 2Respiratory involvement in Sjogren\'s Syndrome*Common manifestations:***1. Cough due to dry airways2. Bronchiolitis3. Bronchiectasis4. Interstitial Lung Disease** most common Non specific Interstitial Pneumonitis (NSIP), other patterns include UIP (Usual Interstitial Pneumonitis), LIP (Lymphocytic Interstitial Pneumonitis), Organising Pneumonia**5. Recurrent Chest Infections***Rare manifestations***1. Pulmonary Lymphoma2. Pulmonary Amyloidosis3. Pulmonary Hypertension**

In conclusion, we describe here a rare presentation of pulmonary amyloidosis secondary to Sjogren\'s syndrome (SS) that has not been yet been described in indigenous population to the best of our knowledge. Our case and review also adds up to the literature on the pulmonary manifestations of Amyloidosis and Sjogren\'s Syndrome. The case represented here also highlights the role of surgical lung biopsy in the diagnosis of the condition.
